|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|1.||Pettit, George R: 22 articles (07/2010 - 09/2002)|
|2.||Pettit, Robin K: 12 articles (07/2010 - 02/2003)|
|3.||Doubek, Dennis L: 12 articles (03/2010 - 09/2002)|
|4.||Herald, Delbert L: 9 articles (07/2010 - 08/2003)|
|5.||Meng, Yanhui: 7 articles (07/2010 - 02/2003)|
|6.||Chapuis, Jean-Charles: 7 articles (07/2007 - 02/2003)|
|7.||Tan, Rui: 5 articles (07/2007 - 09/2002)|
|8.||Knight, John C: 5 articles (01/2006 - 02/2003)|
|9.||Schmidt, Jean M: 5 articles (05/2005 - 02/2003)|
|10.||Hibasami, H: 5 articles (05/2001 - 07/2000)|
|1.||Cytarabine (Cytosar-U)FDA LinkGeneric
01/01/1986 - "Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?"
01/01/1983 - "While the majority of patients under 70 years of age with acute non-lymphocytic leukemia enter remission when treated with a combination of cytosine arabinoside and an anthracycline antibiotic, 20-45% of patients do not. "
04/01/1994 - "The in vitro growth inhibitory activities of the ara-C derivatives (4) against murine lymphocytic leukemia L1210 cells indicate that prodrug to drug conversion readily occurs. "
01/20/1990 - "A case of two repeated CNS recurrences of acute non-lymphocytic leukemia (M2) was treated with intermediate dose Ara-C therapy and achieved 2 complete remissions. "
01/20/1990 - "[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]."
|2.||Daunorubicin (Cerubidine)FDA LinkGeneric
04/01/1998 - "The aim of this study was to evaluate the frequency and the role of a PGP and an LRP overexpression in affecting the intracellular daunorubicin accumulation (IDA) and in predicting the therapy outcome on a subset of overt secondary acute non lymphocytic leukemias (ANLL). "
02/01/1986 - "A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia."
05/01/1995 - "An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children."
01/01/1990 - "Intracellular pH (pHi) of mouse lymphoid leukemia P388 cells was measured at the wavelength of 518 and 570 nm of fluorescein: pHi of rubomycin-sensitive P388 cells was higher than pHi of the cells resistant to this antitumour antibiotic (6.98 +/- 0.04 and 6.63 +/- 0.03, respectively, P less than 0.001). "
10/01/1989 - "In vitro chemosensitivity of blast cells from 19 patients, affected by acute non-lymphocytic leukemia, to cytosine arabinoside and daunorubicin was investigated. "
|3.||Doxorubicin (Adriamycin)FDA LinkGeneric
12/31/2008 - "In the present study, we demonstrate that JNK stimulates PKCdelta gene expression via c-Jun and ATF2 in response to the anticancer agent doxorubicin (DXR) in mouse lymphocytic leukemia L1210 cells. "
09/01/2006 - "They were evaluated in P388 murine lymphocytic leukemia cell line (P388) in vitro using SRB assay for cytotoxicity and in adriamycin-resistant P388 murine lymphocytic leukemia cell line (P388/ADR) using MTT assay for resistant reversal activity. "
11/01/1992 - "Taking into account the possible regulatory influences of the beta-adrenergic system on lymphocyte proliferation as well as the proposed role of cyclic 3'-5'-adenosine monophosphate (cAMP) in the modulation of multidrug resistance (MDR) in tumour cells, we have tried to assess the status of the interactions between the beta-adrenergic system and a mouse lymphocytic leukemia, the P388, both as a doxorubicin-sensitive (P388) and -resistant (MDR) variant (P388/DXR). "
06/01/1989 - "One representative complex has been screened in vitro and in vivo against P388 lymphocytic leukemia cells sensitive and resistant to adriamycin (P388/S and P388/R). "
01/01/1983 - "A direct splenocyte migration inhibition assay system was used to evaluate cellular sensitization in BDF1 mice carrying intraperitoneal transplants of the lymphocytic leukemia, P388, and its adriamycin-resistant subline, P388/ADR. "
|4.||Etoposide (VP 16)FDA LinkGeneric
12/18/1996 - "A polymerase chain reaction-based technique was used to measure exon 2 + 3 deletions in human lymphoid leukemia CCRF-CEM cells 6 days after either 4-hour or 24-hour treatment with etoposide at clinically relevant concentrations. "
07/01/1991 - "[Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia]."
07/01/1991 - "We investigated the efficacy of oral etoposide (VP-16) for the patients with acute non-lymphocytic leukemia (ANLL) in relapse or refractory to the standard chemotherapy. "
07/01/1993 - "Eight cases with poor prognosis hematological malignancies (non-Hodgkin lymphoma, 6 cases; acute non-lymphocytic leukemia, 2 cases) and nine cases with non-hematological malignancies were treated with high dose etoposide (VP16) containing regimen followed by autologous hemopoietic stem cell transplantation. "
01/01/1985 - "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days. "
|5.||rituximab (Mabthera)FDA Link
12/17/2015 - "To evaluate idelalisib as initial therapy, 64 treatment-naïve older patients with CLL or small lymphocytic leukemia (median age, 71 years; range, 65-90) were treated with rituximab 375 mg/m(2) weekly ×8 and idelalisib 150 mg twice daily continuously for 48 weeks. "
03/01/2015 - "Parallel application of NKG2D-Fc-ADCC with Rituximab caused additive effects in lymphoid leukemia. "
04/15/2001 - "Fifty patients with CLL (n = 40) or other mature B-cell lymphoid leukemias (n = 10) were treated with four weekly infusions of rituximab. "
01/01/2012 - "Rituximab in space: intrapleural and other novel routes of administration for lymphomas and lymphoid leukemias."
01/01/2011 - "Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab."
01/01/2004 - "Therefore, with equivalent efficacy and tolerability to the intravenous preparation, oral fludarabine gives the hematologist an important new option in the management of chronic lymphocytic leukemia."
11/01/2002 - "He had had chronic lymphoid leukemia for 11 years and had been treated 5 months earlier with 3 courses of fludarabine. "
11/01/2002 - "[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia]."
01/01/2000 - "To try effectiveness of fludarabine monotherapy in verified chronic lymphoid leukemia (CLL) in pretreated patients. "
01/01/2000 - "[Fludarabine treatment of chronic lymphoid leukemia]."
|7.||DNA (Deoxyribonucleic Acid)IBA
02/01/2004 - "The DNA of peripheral blood leucocytes from lymphoid leukemia patients were extracted for amplification of the TCR-gamma gene rearrangement with the consensus primers and touch-down PCR. "
12/01/2001 - "These complexes inhibit the growth of P388 lymphocytic leukemia cells and their targets are DNA. "
02/01/2001 - "These agents suppressed P388 lymphocytic leukemia DNA synthesis after 60 min at 100 microM. "
12/01/2000 - "In L1210 lymphoid leukemia cell the complexes inhibited preferentially DNA synthesis over 60 min at 25 to 100 microM. "
06/01/1998 - "In L1210 lymphoid leukemia cells DNA synthesis was significantly suppressed over 60 min by the agents from 25 to 100 microM. "
|8.||Vincristine (Oncovin)FDA LinkGeneric
06/01/1994 - "This results in a dramatic improvement in the therapeutic activity of liposomal vincristine as measured using a murine P388 lymphocytic leukemia model. "
01/01/2013 - "When tested against a broad panel of primary cultures of patient tumor cells (PCPTC) representing different forms of leukemia and solid tumors, VLX40 displayed high activity against both myeloid and lymphoid leukemias in contrast to the reference compound vincristine to which myeloid blast cells are often insensitive. "
01/01/2002 - "Multidrug resistance (MDR) lines from a murine T-cell lymphoid leukemia were selected in increasing vincristine (VCR) or doxorubicin (DOX) concentrations. "
01/01/2002 - "Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia."
02/01/1990 - "Liposome encapsulation of vincristine also enhanced the antitumor activity against murine P388 and L1210 lymphocytic leukemia models. "
|9.||Mitoxantrone (Novantrone)FDA LinkGeneric
12/01/1998 - "In a phase I-II study, the authors evaluated the intracellular pharmacokinetics, toxicity, and efficiency of a high dose of mitoxantrone given as first induction in acute non-lymphocytic leukemia. "
01/01/1985 - "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy. "
12/01/1998 - "High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study."
01/01/1996 - "Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia."
01/01/1991 - "P388/R, the adriamycin (ADR) resistant subline of murine P388 lymphocytic leukemia was cross-resistant to the drug mitoxantrone (MTN). "
|10.||Prednisolone (Predate)FDA LinkGeneric
01/01/2009 - "Comparative study of immunological phenotype of lymphoid cells of peripheral blood of patients with chronic lymphoid leukemia (CLL) and immune cytopenia at the treatment with prednisolone and chlorambucil has been carried out. "
01/01/2009 - "[Immunological profile of lymphoid cells in patients with chronic lymphoid leukemia and immunological complications during the treatment with prednisolone and chlorambucil]."
03/01/1981 - "[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)]."
12/01/2010 - "Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin."
01/20/1990 - "A 55-year-old male with acute non-lymphocytic leukemia (M2) achieved complete remission by combination chemotherapy of Behenoyl-ara-C, Daunorubicin, 6-Mercaptopurine and Prednisolone in July, 1985. "
|1.||Drug Therapy (Chemotherapy)
01/01/1986 - "HMC lymphoid leukemia appears to differ from typical adult ALL in that it has a female predominance, a relatively indolent early clinical course that lasts 1 year or longer, and it manifests the possibility of survival for 1 or 2 years despite the failure to achieve a complete remission with chemotherapy. "
02/01/1979 - "Overshoot phenomenon of phytohemagglutinin response after chemotherapy and its relationship to remission in acute non-lymphocytic leukemia."
03/15/1980 - "Induced acute non-lymphocytic leukemia following long-term chemotherapy: a study of 20 cases."
11/01/2015 - "Chemotherapy Exposure and outcomes Among Patients Diagnosed with Chronic Lymphoid Leukemia."
01/01/2013 - "Now, we reveal that ASPP2 expression is significantly attenuated in acute myeloid and lymphoid leukemia - especially in patients with an unfavorable prognostic risk profile and patients who fail induction chemotherapy. "
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
04/01/1991 - "One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than 56 years were allocated to receive either allogeneic (allo-BMT) or autologous bone marrow transplantation (auto-BMT) when first complete remission (CR1) was achieved. "
08/01/1991 - "These results suggest that autologous bone marrow transplantation purged with 4HC is an effective and useful treatment for children with acute non-lymphocytic and lymphocytic leukemia who have no HLA-identical donor."
12/01/2006 - "Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation."
04/01/1991 - "Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission."
07/01/2003 - "Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia."
|3.||Transplantation (Transplant Recipients)
07/01/1989 - "Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission."
02/01/1990 - "Of 13 patients with acute non-lymphocytic leukemia and variants (11 who were transplanted in relapse) three died without relapse, three have relapsed and seven survive disease free from 9 to 27 months (median 20 months) after transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)"
04/01/2013 - "After injection into NOD/SCID mice, these cells induced myeloid and lymphoid leukemias, whereas transplantation of control (nontransduced) hematopoietic cells failed to produce any hematopoietic reconstitution in vivo. "
01/01/2009 - "[Characteristics of the morphofunctional condition of cell populations by the modal cell class in response to transplantation of lymphocytic leukemia p-388]."
01/01/1992 - "The survival effect for the conjugate was assessed in vivo against p388 lymphocytic leukemia in female CDF1 mice by intraperitoneal (i.p.) transplantation/i.p. "
|4.||Combination Drug Therapy (Combination Chemotherapy)
07/01/1983 - "Twenty-two patients with adult acute non-lymphocytic leukemia treated with intensive combination chemotherapy between November 1975 and April 1982 were retrospectively analyzed to see if we could find useful clinical parameters which could predict those patients who, after failing their initial treatment cycle, would respond to subsequent cycles of the same regimen. "
08/15/1980 - "Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia."
03/01/1971 - "Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia."
12/01/2006 - "This review will summarize recent advances in the biology and the management of chronic lymphocytic leukemia, including prognostic factors, pointing mainly on combination chemotherapy based on nucleoside analogs and monoclonal antibodies. "
11/01/1982 - "[DCTP (I) combination chemotherapy of adult acute non-lymphocytic leukemia]."
02/04/2003 - "The underlying diseases of the patients were lymphocytic leukemia and genetic deficiency of the immune system, and they survived between 1 and 9 months after transplant. "
04/01/1997 - "Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia."
02/01/2000 - "Allogeneic CD34-selected peripheral stem cell transplant for acute non-lymphocytic leukemia (FAB M5a) developed from juvenile chronic myelogenous leukemia."
04/01/1993 - "Four patients were diagnosed of pulmonary toxoplasmosis, three being immunosuppressed (one renal transplant, one with chronic lymphoid leukemia and one intravenous drug user HIV seronegative) and the remaining one healthy. "
07/01/1994 - "Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia."